HaploX, a global leader in next-generation sequencing solutions, today announced the commercial launch of four highly-anticipated reagent kits designed to accelerate precision oncology from discovery to post-treatment monitoring. The new kits—CorePanel: Clinical 136, StarPanel: Clinical 1326, mClear: Personalized MRD, and mClean (Digestive-Tract): fixed panel MRD—deliver comprehensive genomic profiling and ultra-sensitive minimal residual disease (MRD) detection for solid-tumor patients and their clinicians.

CorePanel Clinical 136

A streamlined, 136-gene targeted sequencing kit optimized for routine clinical labs. CorePanel covers almost all guideline-recommended solid-tumor biomarkers in a single, cost-effective assay, enabling same-day sample-to-report workflows.

StarPanel Clinical 1326

The most expansive solid-tumor panel in the company’s portfolio, interrogating 1,326 genes with high-resolution coverage. StarPanel is purpose-built for high-complexity clinical cases that require deep, discovery-grade genomic data.

mClear Personalized MRD

Leveraging personalized, tumor-informed assays, mClear delivers industry-leading analytical minimum detection limit down to 0.005%. It is designed for longitudinal monitoring of any solid-tumor patient, providing oncologists with early relapse signals months ahead of traditional imaging.

mClean (Digestive-Tract) fixed panel MRD

A fixed-content MRD kit specifically optimized for colorectal, gastric, esophageal, and other gastrointestinal cancers. mClean combines ultra-efficient library prep with proprietary error-suppression chemistry, ensuring robust detection of low-abundance circulating tumor DNA (ctDNA) in challenging sample types.

All four kits integrate seamlessly with HaploX’s automated library-preparation ecosystem and cloud/local-based bioinformatics platform, enabling end-to-end traceability and compliance with global regulatory standards.